Where is Norgine located?

Norgine is headquartered in Amsterdam, Netherlands.

How many employees does Norgine have?

As of Jun 30, 2026, the latest employee count at Norgine is 1182.

Is Norgine a funded company?

Norgine is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Venture Debt round.

When was the latest funding round of Norgine?

Norgine's latest funding was a $***** Conventional Debt round, with participation from 0 investor.

Where does Norgine rank among its competitors?

Norgine ranks 166th amongst 2534 active competitors, of which 856 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Norgine?

Norgine's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Norgine - 2026 Company Profile, Funding & Competitors

Norgine is an acquired company based in Amsterdam (Netherlands), founded in 1906. It operates as a Pharmaceutical company developing and marketing proprietary therapeutic products for gastrointestinal diseases. Norgine has raised an undisclosed amount in funding. The company has 2534 active competitors, including 856 funded and 642 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Norgine is engaged in developing and marketing its own therapeutic products primarily in the field of gastrointestinal diseases. Other therapeutic areas covered include hepatology and critical care. The company has a portfolio of 9 products which generated revenue of EUR 300M for 2015. The company also has a portfolio of 7 pipeline candidates out of which 5 are for gastroenterology and 2 for critical care

Website: norgine.com
Social

Key Metrics

Founded Year

1906

Location

Amsterdam, Netherlands

Stage

Acquired

Latest Funding Round

Conventional Debt, $*****

Investors

Digital Pharma Lab

Ranked

166^th among 2534 active competitors

Employee Count

1,182 as on Jun 30, 2026

Investment & Acquisitions

Theravia & 3 more

Similar Companies

Ironwood Pharma & 152 more

Exit Details

Acquired by Goldman Sachs (May 26, 2022)

View Norgine's full profile

Norgine got acquired by Goldman Sachs on May 26, 2022.

Click here to take a look at Norgine's acquisition in detail

Norgine has raised funding over 2 rounds. Norgine has 1 institutional investor.

View details of Norgine's funding rounds and investors

Norgine's employee count trend

Norgine has 1,182 employees as of Jun 26. Here is Norgine's employee count trend over the years:

Uncover Norgine's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Norgine include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Norgine, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
166th	Norgine 1906, Amsterdam (Netherlands), Acquired	Pharmaceutical company developing and marketing proprietary therapeutic products for gastrointestinal diseases	-	Digital Pharma Lab	59/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Norgine's competitors? Click here to see the top ones

Norgine has made 1 investments in companies including Medical Vision. Norgine has also acquired 3 companies including Theravia and Azanta.

Here is the list of investments & acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 15, 2025	Acquisition	Theravia		Reuilly (France)
Mar 24, 2020	Acquisition	Azanta	1994	Copenhagen (Denmark)
May 11, 2017	Acquisition	Merus Labs	2009	Toronto (Canada)